News
NewS Releases
July 10, 2025: Chris Wagner: The role of Eden Radioisotopes in the future of nuclear medicine
Chris Wagner has more than 40 years of experience in nuclear medicine, beginning as a clinical practitioner before moving into leadership roles at companies like Mallinckrodt (now Curium) and Nordion. His knowledge of both the clinical and the manufacturing sides of nuclear medicine laid the groundwork for helping to found Eden Radioisotopes, a start-up venture that intends to make diagnostic and....
New Generation Nuclear Radioisotope Reactor Infrastructure to Power the Future of Cancer Diagnosis and Treatment
Investors have a rare chance to lead and shape the only purpose-
built, low-cost, North-American isotope platform just as demand
explodes and legacy reactors retire.
Acting now secures a preferred position for follow-on rounds,
aligns capital with life-saving impact, and targets venture-style
multiples backed by long-term infrastructure economics...
May 7, 2025: Eden Radioisotopes and Cross River Infrastructure Partners Sign MOU to Explore Development of a New Generation Medical Radioisotope Reactor in New Brunswick
Eden Radioisotopes, LLC ("Eden") and Cross River Infrastructure Partners, LLC ("CRIP") are pleased to announce the execution of a Memorandum of Understanding (MOU) to jointly explore the...
November 21, 2019: Eden Radioisotopes, LLC and Sandia National Laboratories Earn 2019 Technology Transfer Award From the Federal Laboratory Consortium, Mid-Continent Region
Eden Radioisotopes, LLC, an Albuquerque, NM, startup company, and Sandia National Laboratories earned a regional Federal Laboratory Consortium (FLC) award recognizing federal laboratories and their partners for outstanding work to develop and commercialize innovative technologies.
May 22, 2019: Eden Radioisotopes, LLC, Secures Reactor Project Funding for Medical Isotope Production
Eden Radioisotopes, LLC, an Albuquerque, NM startup company, is pleased to announce an investment agreement with Abo Empire, LLC, a Yates Family company. This investment funds the company project to build a reactor of less than 2MW in New Mexico for the purpose of producing medical isotopes, primarily Molybdenum-99. Known as Moly-99 for short, this isotope is a critical raw material for Technetium-99m, used extensively in medical molecular...